Paraneoplastic endocrinopathy in Castleman disease and POEMS syndrome

Polyneuropathy, organomegaly, endocrinopathy, M-protein, skin changes (POEMS) syndrome is a rare paraneoplastic syndrome associated with Castleman disease, monoclonal gammopathy of undetermined significance, symptomatic hemoblastosis or systemic autoimmune diseases. Slow development, nonspecifity of most clinical manifestations and lack of awareness of physicians are the main reasons for the late access to medical care and a long, sometimes many years, diagnostic search. Even after diagnosis, the use of modern methods of immunosuppressive, immunomodulating or antitumor therapy is significantly limited by the difficulties of taxonomic classification of the diagnosis, the lack of unified therapeutic approaches, and related unresolved issues of profiling and drug provision of patients. The article provides an overview of the basic information about the pathogenesis and clinical manifestations of POEMS syndrome. Using the example of a patient with Castleman’s disease, the difficulties of primary diagnosis of POEMS syndrome and the problems of interdisciplinary interaction of doctors of various specialties are demonstrated. The significance of endocrine disorders in the diagnosis and treatment planning is analyzed.

1. Bardwick P.A., Zvaifler N.J., Gill G.N. et al. Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes. Medicine 1980;59(4):311–22.DOI: 10.1097/00005792-198007000-00006.

2. Crow R.S. Peripheral neuritis in myelomatosis. BMJ 1956;2(4996):802–4. DOI: 10.1136/bmj.2.4996.802.

3. Shimpo S., Nishitani H., Tsunematsu T. et al. Solitary plasmacytoma with polyneuritis and endocrine disturbances. Nippon Rinsho 1968;26:2444–56.

4. Saikawa S. On the etiology of “PEP syndrome (a peculiar progressive polyneuritis associated with pigmentation, edema, plasma cell dyscrasia)”. Med J Kagoshima Univ 1980;32:219–43.

5. Driedger H., Pruzanski W. Plasma cell neoplasia with peripheral polyneuropathy. Medicine 1980;59(4):301–10. DOI: 10.1097/00005792-198007000-00005.

6. Takatsuki K., Yodoi J., Uchiyama T. et al. Plasma cell dyscrasia with polyneuropathy and endocrine disorders. Review of 36 cases. Neurol Med 1977;7:483–93.

7. Nakanishi T., Sobue I., Toyokura Y. et al. The Crow–Fukase syndrome: a study of 102 cases in Japan. Neurology 1984; 34(6):712. DOI: 10.1212/wnl.34.6.712.

8. Piradov M.A., Suponeva N.A., Ginzberg S.S. et al. POEMS-syndrome: a literature review and case reports. Zhurnal nevrologii i psihiatrii = Journal of Neurology and Psychiatry 2014;4:4–10. (In Russ.)].

9. Mikhaylov A.M., Bessmeltsev S.S., Ageeva T.A. et al. Castlemans disease with POEMS syndrome: clinical and histopathological feautures with regard to lymph nodes and bone marrow. Byulleten’ sibirskogo otdeleniya Rossijskoy akademii nauk = Bulletin of the Siberian Branch of the Russian Academy of Medical Sciences 2013;(2):63–71. (In Russ.)].].

10. Dispenzieri A. POEMS Syndrome: 2019 Update on diagnosis, risk-stratification, and management. Am J Hematol 2019; 94(7):812–27. DOI: 10.1002/ajh.25495.

11. Kang W.Y., Shen K.N., Duan M.H. et al. 14q32 translocations and 13q14 deletions are common cytogenetic abnormalities in POEMS syndrome. Eur J Haematol 2013;91(6):490–6. DOI: 10.1111/ejh.12189.

12. Bryce A.H., Ketterling R.P., Gertz M.A. et al. A novel report of cig-FISH and cytogenetics in POEMS syndrome. Am J Hematol 2008;83(11):840–1. DOI: 10.1002/ajh.21285.

13. Nagao Y., Mimura N., Takeda J. et al. Genetic and transcriptional landscape of plasma cells in POEMS syndrome. Leukemia 2019;33(7):1723–35. DOI: 10.1038/s41375-018-0348-x.

14. Soubrier M., Labauge P., Jouanel P. et al. Restricted use of lambda genes in POEMS syndrome. Haematologica 2004;89(4):ECR02.

15. Abe D., Nakaseko C., Takeuchi M. et al. Restrictive usage of monoclonal immunoglobulin λ light chain germline in POEMS syndrome. Blood 2008;112(3):836–9. DOI: 10.1182/blood-2007-12-126979.

16. Dispenzieri A. POEMS syndrome. Blood Rev 2007;21(6):285–99. DOI: 10.1016/j.blre.2007.07.004.

17. Soubrier M., Dubost JJ., Serre A.F. et al. Growth factors in POEMS syndrome: evidence for a marked increase in circulating vascular endothelial growth factor. Arth Rheumat 1997;40(4):786–7. DOI: 10.1002/art.1780400430.

18. Kanai K., Sawai S., Sogawa K. et al. Markedly upregulated serum interleukin- 12 as a novel biomarker in POEMS syndrome. Neurology 2012;79(6):575–82. DOI: 10.1212/wnl.0b013e318263c42b.

19. Gheradi R., Belec L., Soubrier M. et al. Overproduction of proinflammatory cytokines imbalanced by their antagonists in POEMS syndrome. Blood 1996;87(4): 1458–65. DOI: 10.1182/blood.v87.4.1458.bloodjournal8741458.

20. Watanabe O., Arimura K., Kitajima I. et al. Greatly raised vascular endothelial growth factor (VEGF) in POEMS syndrome. Lancet 1996;347(9002):702. DOI: 10.1016/s0140-6736(96)91261-1.

21. Soubrier M., Guillon R., Dubost J.J. et al. Arterial obliteration in POEMS syndrome: possible role of vascular endothelial growth factor. J Rheumatol 1998;25(4):813–15.

22. Watanabe O., Maruyama I., Arimura K. et al. Overproduction of vascular endothelial growth factor/vascular permeability factor is causative in Crow–Fukase (POEMS) syndrome. Muscle Nerve 1998;21(11):1390–7. DOI: 10.1002/(SICI)1097-4598(199811) 21:11<1390::AID-MUS5>3.0.CO;2-4.

23. Nishi J., Arimura K., Utsunomiy A. et al. Expression of vascular endothelial growth factor in sera and lymph nodes of the plasma cell type of Castleman’s disease. Br J Haematol 1999;104(3):482–5. DOI: 10.1046/j.1365-2141.1999.01208.x.

24. Soubrier M., Sauron C., Souweine B. et al. Growth factors and proinflammatory cytokines in the renal involvement of POEMS syndrome. Am J Kidney Dis 1999;34(4):633–8. DOI: 10.1016/s0272-6386(99)70386-0.

25. Niimi H., Arimura K., Jonosono M. et al. VEGF is causative for pulmonary hypertension in a patient with Crow–Fukase (POEMS) syndrome. Int Med 2000;39(12):1101–4. DOI: 10.2169/internalmedicine.39.1101.

26. Scarlato M., Previtali S.C., Carpo M. et al. Polyneuropathy in POEMS syndrome: role of angiogenic factors in the pathogenesis. Brain 2005;128(8):1911–20. DOI: 10.1093/brain/awh519.

27. Kuwabara S., Misawa S., Kanai K. et al. Autologous peripheral blood stem cell transplantation for POEMS syndrome. Neurology 2005;66(1):105–7. DOI: 10.1212/01.wnl.0000188757.38495.23.

28. Mineta M., Hatori M., Sano H. et al. Recurrent Crow–Fukase syndrome associated with increased serum levels of vascular endothelial growth factor: a case report and review of the literature. Tohoku J Exp Med 2006;210(3):269–77. DOI: 10.1620/tjem.210.269.

29. D’Souza A., Hayman S.R., Buadi F. et al. The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome. Blood 2011;118(17):4663–5. DOI: 10.1182/blood-2011-06-362392.

30. Kanai K., Kuwabara S., Misawa S. et al. Failure of treatment with anti-VEGF monoclonal antibody for long-standing POEMS syndrome. Int Med 2007;46(6):311–3. DOI: 10.2169/internalmedicine.46.6246.

31. Straume O., Bergheim J., Ernst P. Bevacizumab therapy for POEMS syndrome. Blood 2006;107(12):4972–4. DOI: 10.1182/blood-2005-12-5045.

32. Dietrich P.Y., Duchosal M.A. Bevacizumab therapy before autologous stem-cell transplantation for POEMS syndrome. Annal Oncol 2007;19(3):595. DOI: 10.1093/annonc/mdm602.

33. Badros A., Porter N., Zimrin A. Bevacizumab therapy for POEMS syndrome. Blood 2005;106(3):1135. DOI: 10.1182/blood-2005-03-0910.

34. Ohwada C., Nakaseko C., Sakai S. et al. Successful combination treatment with bevacizumab, thalidomide and autologous PBSC for severe POEMS syndrome. Bone Marr Transplant 2008;43(9):739–40. DOI: 10.1038/bmt.2008.381.

35. Samaras P., Bauer S., Stenner-Liewen F. et al. Treatment of POEMS syndrome with bevacizumab. Haematologica 2007;92(10): 1438–9. DOI: 10.3324/haematol.11315.

36. Sekiguchi Y., Misawa S., Shibuya K. et al. Ambiguous effects of anti-VEGF monoclonal antibody (bevacizumab) for POEMS syndrome. J Neurol 2013;84(12):1346–8. DOI: 10.1136/jnnp-2012-304874.

37. Endo I., Mitsui T., Nishino M. et al. Diurnal fluctuation of edema synchronized with plasma VEGF concentration in a patient with POEMS syndrome. Int Med 2002;41(12):1196–8. DOI: 10.2169/internalmedicine.41.1196.

38. Nakano A., Mitsui T., Endo I. et al. Solitary plasmacytoma with VEGF overproduction: report of a patient with polyneuropathy. Neurology 2001; 56(6):818–9. DOI: 10.1212/wnl.56.6.818.

39. Koga H., Tokunaga Y., Hisamoto T. et al. Ratio of serum vascular endothelial growth factor to platelet count correlates with disease activity in a patient with POEMS syndrome. Eur J Int Med 2002;13(1):70–4. DOI: 10.1016/s0953-6205(01)00199-6.

40. Wang C., Huang X.F., Cai Q.Q. et al. Remarkable expression of vascular endothelial growth factor in bone marrow plasma cells of patients with POEMS syndrome. Leuk Res 2016;50:78–84. DOI: 10.1016/j.leukres.2016.09.017.

41. Lavenstain B., Dalakas M., Engel W.K. et al. Polyneuropathy in non-secretory osteosclerotic multiple myeloma with immunoglobulin deposition in peripheral nerve tissue. Neurology 1979;29:611.

42. Ghandi G.Y., Basu R., Dispenzieri A. et al. Endocrinopathy in POEMS syndrome: the Mayo clinic experience. Mayo Clinic Proc 2007 l;82(7):836–42. DOI: 10.4065/82.7.836.

43. Gherardi R., Baudrimont M., Kujas M. et al. Pathological findings in three non- japanese patients with the POEMS syndrome. Virch Arch Pathol Anat Histopathol 1988;413(4):357–66. DOI: 10.1007/bf00783029.

44. Allam J.S., Kennedy C.C., Aksamit T.R. et al. Pulmonary manifestations in patients with POEMS syndrome. Chest 2008;133(4):969–74. DOI: 10.1378/chest.07-1800.

45. Barete S., Mouawad R., Choquet S. et al. Skin manifestations and vascular endothelial growth factor levels in POEMS syndrome. Arch Dermatol 2010;146(6). DOI: 10.1001/archdermatol.2010.100.

46. Distler O., Del Rosso A., Giacomelli R. et al. Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arths Res 2002;4(6):R11. DOI: 10.1186/ar596.

47. Miest R.Y.N., Comfere N.I., Dispenzieri A. et al. Cutaneous manifestations in patients with POEMS syndrome. Int J Dermatol 2013;52(11):1349–56. DOI: 10.1111/j.1365-4632.2012.05648.x.

48. Dispenzieri A. POEMS syndrome: update on diagnosis, risk-stratification, and management. Am J Hematology 2012;87:805–14.

49. Miralles G.D., O’Fallon J.R., Talley N.J. Plasma-cell dyscrasia with polyneuropathy. New Eng J Med 1992;327(27):1919–23. DOI: 10.1056/nejm199212313272705.

50. Dispenzieri A., Buadi F.K. A review of POEMS syndrome. Cancer Network, 2013. Pp. 1–11.

51. Wang Y., Huang L., Shi Y. et al. Characteristics of 1946 Cases of POEMS syndrome in chinese subjects: a literaturebased study. Front Immunol 2019;10. DOI: 10.3389/fimmu.2019.01428.

52. Dispenzieri A., Kyle R.A., Lacy M.Q. et al. POEMS syndrome: definitions and long-term outcome. Blood 2003;101(7):2496–506. DOI: 10.1182/blood-2002-07-2299.

53. Li J., Zhou D.B., Huang Z. et al. Clinical characteristics and long-term outcome of patients with POEMS syndrome in China. Annal Hematol 2011;90(7):819–26. DOI: 10.1007/s00277-010-1149-0.

54. Kaushik M., Pulido J.S., Abreu R. et al. Ocular findings in patients with polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome. Ophthalmology 2011;118(4):778–82. DOI: 10.1016/j.ophtha.2010.08.013.

55. Mizuiri S., Mitsuo K., Sakai K. et al. Renal involvement in POEMS syndrome. Nephron 1991;59(1):153–6. DOI: 10.1159/000186536.

56. Nakamoto Y., Imai H., Yasuda T. et al. A spectrum of clinicopathological features of nephropathy associated with POEMS syndrome. Nephrol Dialys Transplant 1999;14(10):2370–86. DOI: 10.1093/ndt/14.10.2370.

57. Dispenzieri A. Castleman disease. Rare Hematological Malignancies Springer US. Pp. 293–330. Available at: http://dx.doi.org/10.1007/978-0-387-73744-7_13.

58. Yu L., Tu M., Cortes J. et al. Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease. Blood 2017;129(12):1658–68. DOI: 10.1182/blood-2016-11-748855.

59. Li H., Huang Y., Li Y. et al. Endocrine manifestations in POEMS syndrome: a case report and literature review. BMC Endocr Disord 2019;19(1):33. DOI: 10.1186/s12902-019-0355-6.

60. Caimari F., Keddie S., Lunn M.P. et al. Prevalence and course of endocrinopathy in POEMS syndrome. J Clin Endocrinol Metabol 2018;104(6):2140–6. DOI: 10.1210/jc.2018-01516.

61. Lewandowski K., Al-Din A., Spencer N. et al. Addisonian crisis in a patient with a progressive polyneuropathy. Endocr Abstr 2003;5:19. Available at: https://www.endocrine-abstracts.org/ea/0005/ea0005p19.

62. Prokop J., Estorninho J., Marote S. et al. POEMS syndrome: a rare cause of adrenal insufficiency in a young male. Endocrinol Diabet Metabol Case Rep 2019. DOI: 10.1530/EDM-19-0010.

63. Bruno C., Fleck J., Cavaghan M. Pituitary macroadenoma in a patient with poems syndrome in conjunction with Castleman disease: first report of a case and review of related literature. Endocr Pract 2010;16(1):97–101. DOI: 10.4158/ep09027.crr.

64. Rajkumar S., Dimopoulos M.A., Palumbo A. et al. Interntional Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncology 2014:15(12):538–48. DOI: 10.1016/S1470-2045(14)70442-5.

65. Dao L.N., Hanson C.A., Dispenzieri A. et al. Bone marrow histopathology in POEMS syndrome: a distinctive combination of plasma cell, lymphoid, and myeloid findings in 87 patients. Blood 2011;117(24):6438–44. DOI: 10.1182/blood-2010-11-316935.